FormLyophilised:Reconstitute with 200µl of sterile water. Please note that if you receive this product in liquid form it has already been reconstituted as described and no further reconstitution is necessary.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term.
Storage bufferPBS, pH 7.4, no preservative, sterile filtered
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Use a concentration of 0.1 - 0.2 µg/ml.
Use at an assay dependent dilution. Allows the detection of 0.2 - 0.4 ng/well of recombinant hSCF (using 100µl/well antibody solution).
Use a concentration of 0.008 - 0.012 µg/ml. for one-half maximal inhibition [ND50] of the biological activity of hSCF (10.0 ng/ml).
Use a concentration of 0.5 - 1 µg/ml.
FunctionLigand for the receptor-type protein-tyrosine kinase KIT. Plays an essential role in the regulation of cell survival and proliferation, hematopoiesis, stem cell maintenance, gametogenesis, mast cell development, migration and function, and in melanogenesis. KITLG/SCF binding can activate several signaling pathways. Promotes phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, and subsequent activation of the kinase AKT1. KITLG/SCF and KIT also transmit signals via GRB2 and activation of RAS, RAF1 and the MAP kinases MAPK1/ERK2 and/or MAPK3/ERK1. KITLG/SCF and KIT promote activation of STAT family members STAT1, STAT3 and STAT5. KITLG/SCF and KIT promote activation of PLCG1, leading to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. KITLG/SCF acts synergistically with other cytokines, probably interleukins.
Involvement in diseaseHyperpigmentation with or without hypopigmentation, familial progressive Deafness, congenital, unilateral or asymmetric
Sequence similaritiesBelongs to the SCF family.
Developmental stageActs in the early stages of hematopoiesis.
Post-translational modificationsA soluble form (sKITLG) is produced by proteolytic processing of isoform 1 in the extracellular domain. Found in two differentially glycosylated forms, LMW-SCF and HMW-SCF. LMW-SCF is fully N-glycosylated at Asn-145, partially N-glycosylated at Asn-90, O-glycosylated at Ser-167, Thr-168 and Thr-180, and not glycosylated at Asn-97 or Asn-118. HMW-SCF is N-glycosylated at Asn-118, Asn-90 and Asn-145, O-glycosylated at Ser-167, Thr-168 and Thr-180, and not glycosylated at Asn-97. A soluble form exists as a cleavage product of the extracellular domain.
ab9716 staining SCF in human pancreatic adenocarcinoma tissue section by Immunohistochemistry (Formalin/PFA fixed paraffin-embedded sections). Tissue underwent proteinase K mediated antigen retrieval at room temperature. The primary antibody was used at 0.5 ug/ml and incubated with sample at 4°C overnight. A HRP-labeled polymer detection system was used with an alcohol-soluble AEC chromogen.
Western blot - Anti-SCF antibody (ab9716)
Anti-SCF antibody (ab9716) at 0.1 µg/ml + Recombinant human SCF protein (ab9717) at 0.01 µg
Secondary Goat Anti-Rabbit IgG H&L (HRP) preadsorbed (ab97080) at 1/5000 dilution developed using the ECL technique
Exposure time : 30 seconds
References for Anti-SCF antibody (ab9716)
has not yet been referenced specifically in any publications.
Publishing research using ab9716? Please let us know so that we can cite the reference in this datasheet.
Concentration of lot no. is
Concentration not available for this lot.
Find concentration of your lot:
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"